(NYSE American: MAIA) Announces First Patient Dosed In Key Phase 2 Trial (International Milestone)

*Sponsored

July 17th

Greetings, Friend!

This innovative biotech company is gaining attention in the medical field for its unique approach to cancer treatment.

By targeting the fundamental drivers of tumor growth, the company is working to overcome challenges that have limited the success of existing therapies.

Recent clinical results have shown promising progress, and the team behind this work brings strong expertise and a clear dedication to improving patient outcomes.

As the focus on advanced oncology solutions continues to grow, this company is emerging as a standout in the space.

And here’s what adds to the story: this isn’t a new name I'm bringing to you.

First brought up a few months ago, it moved from an alert price of roughly $1.95 to a high of $2.74 in May.

That marks a short-term move of approximately 40%.

Once again consider this breakout idea for your watchlist:

MAIA Biotechnology, Inc. (NYSE American: MAIA)

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.

Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

Find Key Company Details Here: MAIA Website. MAIA Presentation.

These 5 Explosive Potential Catalysts Could Generate Breakout Buzz For (NYSE American: MAIA)

#1. Major Analyst Target Suggest Serious Upside Potential (Triple-Digit!).

Noble Capital Markets - $14.00 Target - (Potential upside of 700+% from Wednesday's close.)

Key Report Details:

Conclusion. Roche becomes the third pharmaceutical company to make a supply agreement with MAIA to test a checkpoint inhibitor in combination with THIO. We believe this shows that potential partners have noticed the data showing improved overall survival (OS), progression free survival (PFS), and the side effect profile. Clinical data from the three of the eight approved checkpoint inhibitors could make bidding for a marketing partnership more competitive. We are reiterating our Outperform rating and $14 price target.

#2. MAIA Has A Relatively Low Float (Volatility Potential May Be Explosive).

Sporting a float of roughly 25.65Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash.

#3. MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

The expansion of MAIA Biotechnology’s Phase 2 trial for ateganosine in advanced NSCLC marks a key international milestone, significantly expanding patient recruitment.

Promising survival data—median OS of 17.8 months vs. 5-6 months for standard chemotherapy—positions MAIA as a potential first-mover in a multi-Bn-dollar market with no current standard of care.

#4. MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

The agreement with Roche boosts MAIA Biotechnology’s development of ateganosine by enabling clinical studies with Roche’s checkpoint inhibitor atezolizumab.

This partnership validates ateganosine’s potential and supports its use in hard-to-treat cancers, enhancing MAIA’s credibility and opening new opp's for combination therapies in oncology.

#5. MAIA Has Multiple, Potential Value-Driving Milestones In The Near Future.

-----

Coverage is officially reinitiated on MAIA Biotechnology, Inc. (NYSE American: MAIA).

I'll be in touch with updates when necessary. Talk again soon.

All the best,

Dane James

Editor Market Pulse Today

(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/17/2025 and ending on 07/17/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US).

Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-g2bpp/#details

(NYSE American: MAIA) Announces First Patient Dosed In Key Phase 2 Trial (International Milestone)

0 Response to "(NYSE American: MAIA) Announces First Patient Dosed In Key Phase 2 Trial (International Milestone)"

Post a Comment